To generate G12Ci-resistant cell lines, we cultured KRAS-G12C–mutant cells, including Calu1 (a human NSCLC cell line) and MIA PaCa-2 (a human PDAC cell line), with increasing concentrations of G12Ci MRTX849 (100 nM-50,000 nM) for 6 months (29) and we maintained the resistant cell lines with the clinical relevant dose of MRTX849 (1000 nM). Here, KRAS is linked to non-small cell lung carcinoma.